Aerocrine’s NIOX MINO® device for measuring FeNO receives approval by Health Canada

SOLNA, Sweden – 16 April, 2013 - Aerocrine AB (OMX Nordic Exchange: AERO)
announces that Health Canada’s Therapeutic Products Directorate has authorized
Aerocrine’s latest NIOX MINO® for use in identifying allergic airway
inflammation.
NIOX MINO measures fractional exhaled nitric oxide (FeNO) which is a direct, non
-invasive way to assess the allergic airway inflammation which characterizes
many adults and children with asthma. Physicians use FeNO to identify allergic
airway inflammation in patients with suspected asthma, to help predict patient
response to corticosteroid therapy, as well as to help assess adherence to
corticosteroid therapy.

According to the Canadian Asthma Society, asthma affects approximately three
million Canadians and thirteen percent of Canadian children. Asthma is also the
leading cause of absenteeism from school and is the primary reason for emergency
room visits among school age children. As stated in the Canadian Asthma
Guidelines, the goal of asthma management is to reduce airway inflammation.

“This device provides me with a measurement of allergic airway inflammation that
is non-invasive and is an easy 10-second test for patients,” said Dr. Harold
Kim, allergist in Kitchener, Ontario, with appointment at McMaster University.
“Asthma is by definition a chronic inflammatory disease of the airways and this
test adds a new dimension in managing patients that routine available tests are
not able to provide.”

“The approval in Canada is another step forward for Aerocrine and means that
Aerocrine’s innovative technology will now be available throughout North
America. We are actively evaluating our distribution needs in Canada in light of
this important approval,” said Ken Marshall, President Aerocrine, Inc.

Asthma is a chronic inflammatory disease of the airways characterized by
symptoms including wheezing, cough and shortness of breath. The disease affects
more than 300 million people around the world, many of whom are children. Asthma
is a complex disease for which there is no cure. Current therapy is focused on
controlling the disease.

For more information, contact:

Ken Marshall, President, Aerocrine Inc., Phone: 1 (919) 280 9687

Kathy Hodgdon, Sr Director, Business Development, Alternate Channels, Phone: 1
(314) 566 8546

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: 1 (970) 368 0336 or
+46 768 788 379

About Aerocrine

Aerocrine AB is a medical products company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in technology to monitor and manage airway inflammation, Aerocrine
markets NIOX MINO®. This product enables fast and reliable management of airway
inflammation and may therefore play a critical role in more effective diagnosis,
treatment and follow-up of patients with inflammatory airway diseases such as
asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany,
Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock
Exchange in 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 8:00 a.m. on April 16, 2013